Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

ACC 2024 | PREVENT Study

The use of intravascular imaging to identify vulnerable plaque (VP) has proven to be very useful, as such plaque is associated with an increase in major adverse cardiac events. Optimal medical treatment is currently considered the standard strategy to stabilize VP. However, the safety and effectiveness of preventive treatment with percutaneous coronary intervention (PCI) in VP are still unclear.

ACC 2024

The aim of this randomized controlled study was to evaluate whether preventive PCI of VP improves clinical outcomes compared with medical treatment alone.

The primary endpoint (PEP) was target-vessel failure (TVF), defined as a set of events including death from cardiac causes, myocardial infarction related to the treated vessel, ischemia-driven target-vessel revascularization, or hospitalization for unstable or progressive angina after 2 years of randomization. VP lesions to be assessed were defined as coronary stenosis greater than 50% with negative coronary fraction flow reserve (FFR) (≥0.80) along with two of the following criteria: minimum luminal area (MLA) ≤4 mm2, plaque volume >70%, presence of thin-cap fibroatheroma identified through optical coherence tomography (OCT) or intravascular ultrasound (IVUS), and presence of lipid-rich plaque identified by near-infrared spectroscopy (NIRS).

Read also: ACC 2024 | DanGer-Shock Trial.

A total of 1600 patients were analyzed; 800 of them were randomized to the medical treatment alone group and 800 to the preventive PCI plus medical treatment group. Regarding the PFP, the preventive PCI plus medical treatment group had a lower cumulative incidence of TVF at 2 years compared with the medical treatment alone group (preventive PCI 0.4% vs. medical treatment 3.4%; hazard ratio [HR] 0.11 [95% confidence interval (CI) 0.03-0.36], p=0.0003). These results were sustained at 7 years of follow-up, with a lower incidence of TVF in the preventive PCI group (6.5%) compared with the medical treatment alone group (9.4%): HR 0.54 [95% CI 0.33-0.87], p=0.0097.

Conclusions

In conclusion, in this study, preventive PCI along with medical treatment resulted in a lower incidence of major adverse cardiac events compared with medical treatment alone in VP lesions that did not limit coronary flow.

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: PREVENT Preventive PCI versus Medical Therapy Alone for Treatment of Vulnerable Atherosclerotic Coronary Plaques.

Reference: Seung-Jung Park et al. 


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...